drugset / Trial / NCT00554606

Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis

NCT00554606

Phase 2 Completed 115 enrolled Novartis
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.

Timeline

Start
2007-10-11
Primary completion
2009-08-13
Completion
2009-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody 600 mg Intravenous

Indications